Acute Promyelocytic Leukemia (APL) is a unique subtype of acute myeloid leukemia that is highly responsive to minimally myelosuppressive therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We and others have observed a higher than expected incidence of herpes zoster reactivation in APL patients treated with ATO. Memorial Sloan Kettering Cancer Center (MSKCC) has been using ATO since 1997 in all relapsed APL patients, and more recently has included it in our front-line APL regimens. Here we present a retrospective analysis of the factors contributing to herpes zoster reactivation among APL patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187313 | PMC |
| http://dx.doi.org/10.1016/j.leukres.2021.106569 | DOI Listing |
Publication Analysis
Top Keywords
herpes zoster
12
zoster reactivation
12
apl patients
12
arsenic trioxide
8
minimally myelosuppressive
8
myelosuppressive therapy
8
reactivation apl
8
apl
5
trioxide therapy
4
therapy predisposes
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!